Mouwasat Medical Services Company

SASE:4002 Lagerbericht

Marktkapitalisierung: ر.س17.5b

Mouwasat Medical Services Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Mouwasat Medical Services wird ein jährliches Gewinn- und Umsatzwachstum von 16.4% bzw. 11.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.3% betragen.

Wichtige Informationen

16.4%

Wachstumsrate der Gewinne

16.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum15.5%
Wachstumsrate der Einnahmen11.5%
Zukünftige Eigenkapitalrendite24.3%
Analystenabdeckung

Good

Zuletzt aktualisiert09 Dec 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Dec 12
The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Do Mouwasat Medical Services' (TADAWUL:4002) Earnings Warrant Your Attention?

Sep 30
Do Mouwasat Medical Services' (TADAWUL:4002) Earnings Warrant Your Attention?

The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Sep 12
The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Mouwasat Medical Services Company's (TADAWUL:4002) Popularity With Investors Is Clear

Aug 06
Mouwasat Medical Services Company's (TADAWUL:4002) Popularity With Investors Is Clear

Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

Jul 01
Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

Mouwasat Medical Services Company's (TADAWUL:4002) Popularity With Investors Is Clear

Apr 23
Mouwasat Medical Services Company's (TADAWUL:4002) Popularity With Investors Is Clear

Here's Why We Think Mouwasat Medical Services (TADAWUL:4002) Might Deserve Your Attention Today

Mar 18
Here's Why We Think Mouwasat Medical Services (TADAWUL:4002) Might Deserve Your Attention Today

Slowing Rates Of Return At Mouwasat Medical Services (TADAWUL:4002) Leave Little Room For Excitement

Jan 23
Slowing Rates Of Return At Mouwasat Medical Services (TADAWUL:4002) Leave Little Room For Excitement

Here's Why Mouwasat Medical Services (TADAWUL:4002) Has Caught The Eye Of Investors

Dec 17
Here's Why Mouwasat Medical Services (TADAWUL:4002) Has Caught The Eye Of Investors

Mouwasat Medical Services (TADAWUL:4002) Has Some Way To Go To Become A Multi-Bagger

Oct 05
Mouwasat Medical Services (TADAWUL:4002) Has Some Way To Go To Become A Multi-Bagger

Should You Be Adding Mouwasat Medical Services (TADAWUL:4002) To Your Watchlist Today?

Sep 17
Should You Be Adding Mouwasat Medical Services (TADAWUL:4002) To Your Watchlist Today?

The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Jul 03
The Returns At Mouwasat Medical Services (TADAWUL:4002) Aren't Growing

Is Now The Time To Put Mouwasat Medical Services (TADAWUL:4002) On Your Watchlist?

Jun 12
Is Now The Time To Put Mouwasat Medical Services (TADAWUL:4002) On Your Watchlist?

Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down

Feb 24
Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down

Mouwasat Medical Services Company's (TADAWUL:4002) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 18
Mouwasat Medical Services Company's (TADAWUL:4002) Intrinsic Value Is Potentially 25% Below Its Share Price

Return Trends At Mouwasat Medical Services (TADAWUL:4002) Aren't Appealing

Nov 24
Return Trends At Mouwasat Medical Services (TADAWUL:4002) Aren't Appealing

Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down

Aug 24
Returns At Mouwasat Medical Services (TADAWUL:4002) Appear To Be Weighed Down

A Look At The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Jul 01
A Look At The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Time To Worry? Analysts Just Downgraded Their Mouwasat Medical Services Company (TADAWUL:4002) Outlook

May 23
Time To Worry? Analysts Just Downgraded Their Mouwasat Medical Services Company (TADAWUL:4002) Outlook

Mouwasat Medical Services (TADAWUL:4002) Will Pay A Larger Dividend Than Last Year At ر.س2.75

Apr 29
Mouwasat Medical Services (TADAWUL:4002) Will Pay A Larger Dividend Than Last Year At ر.س2.75

Mouwasat Medical Services (TADAWUL:4002) Is Increasing Its Dividend To ر.س2.75

Apr 15
Mouwasat Medical Services (TADAWUL:4002) Is Increasing Its Dividend To ر.س2.75

Investors Will Want Mouwasat Medical Services' (TADAWUL:4002) Growth In ROCE To Persist

Mar 17
Investors Will Want Mouwasat Medical Services' (TADAWUL:4002) Growth In ROCE To Persist

Calculating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Mar 02
Calculating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

If You Like EPS Growth Then Check Out Mouwasat Medical Services (TADAWUL:4002) Before It's Too Late

Feb 15
If You Like EPS Growth Then Check Out Mouwasat Medical Services (TADAWUL:4002) Before It's Too Late

The Return Trends At Mouwasat Medical Services (TADAWUL:4002) Look Promising

Dec 06
The Return Trends At Mouwasat Medical Services (TADAWUL:4002) Look Promising

Do Mouwasat Medical Services's (TADAWUL:4002) Earnings Warrant Your Attention?

Nov 16
Do Mouwasat Medical Services's (TADAWUL:4002) Earnings Warrant Your Attention?

Mouwasat Medical Services (TADAWUL:4002) Is Achieving High Returns On Its Capital

Aug 29
Mouwasat Medical Services (TADAWUL:4002) Is Achieving High Returns On Its Capital

Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

Aug 12
Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

Is Mouwasat Medical Services Company (TADAWUL:4002) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 29
Is Mouwasat Medical Services Company (TADAWUL:4002) Expensive For A Reason? A Look At Its Intrinsic Value

Mouwasat Medical Services' (TADAWUL:4002) Returns On Capital Are Heading Higher

May 26
Mouwasat Medical Services' (TADAWUL:4002) Returns On Capital Are Heading Higher

Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

May 11
Does Mouwasat Medical Services (TADAWUL:4002) Deserve A Spot On Your Watchlist?

Is It Worth Buying Mouwasat Medical Services Company (TADAWUL:4002) For Its 1.4% Dividend Yield?

Apr 13
Is It Worth Buying Mouwasat Medical Services Company (TADAWUL:4002) For Its 1.4% Dividend Yield?

Estimating The Intrinsic Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Mar 16
Estimating The Intrinsic Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Is Mouwasat Medical Services Company's (TADAWUL:4002) Latest Stock Performance Being Led By Its Strong Fundamentals?

Mar 02
Is Mouwasat Medical Services Company's (TADAWUL:4002) Latest Stock Performance Being Led By Its Strong Fundamentals?

Is Mouwasat Medical Services (TADAWUL:4002) A Future Multi-bagger?

Feb 13
Is Mouwasat Medical Services (TADAWUL:4002) A Future Multi-bagger?

Here's Why I Think Mouwasat Medical Services (TADAWUL:4002) Is An Interesting Stock

Feb 01
Here's Why I Think Mouwasat Medical Services (TADAWUL:4002) Is An Interesting Stock

What Kind Of Shareholders Hold The Majority In Mouwasat Medical Services Company's (TADAWUL:4002) Shares?

Jan 17
What Kind Of Shareholders Hold The Majority In Mouwasat Medical Services Company's (TADAWUL:4002) Shares?

What Makes Mouwasat Medical Services Company (TADAWUL:4002) A Great Dividend Stock?

Jan 04
What Makes Mouwasat Medical Services Company (TADAWUL:4002) A Great Dividend Stock?

Mouwasat Medical Services (TADAWUL:4002) Has Gifted Shareholders With A Fantastic 137% Total Return On Their Investment

Dec 21
Mouwasat Medical Services (TADAWUL:4002) Has Gifted Shareholders With A Fantastic 137% Total Return On Their Investment

Estimating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Dec 08
Estimating The Fair Value Of Mouwasat Medical Services Company (TADAWUL:4002)

Mouwasat Medical Services Company's (TADAWUL:4002) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Nov 24
Mouwasat Medical Services Company's (TADAWUL:4002) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Gewinn- und Umsatzwachstumsprognosen

SASE:4002 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SAR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20263,9529719331,19013
12/31/20253,4378086771,00313
12/31/20242,9396607451,25010
9/30/20242,897658542958N/A
6/30/20242,827665484874N/A
3/31/20242,764663521867N/A
12/31/20232,706658527814N/A
9/30/20232,5936598331,034N/A
6/30/20232,501625779970N/A
3/31/20232,431616517779N/A
12/31/20222,334599409707N/A
9/30/20222,226561213572N/A
6/30/20222,208581162542N/A
3/31/20222,177581313642N/A
12/31/20212,144578353683N/A
9/30/20212,125574342657N/A
6/30/20212,143593368643N/A
3/31/20212,085567287537N/A
12/31/20202,045528247481N/A
9/30/20202,016515258529N/A
6/30/20201,911447238520N/A
3/31/20201,889422255533N/A
12/31/20191,857421371635N/A
9/30/20191,808376339548N/A
6/30/20191,769364301548N/A
3/31/20191,717361202509N/A
12/31/20181,67736074386N/A
9/30/20181,652373-2364N/A
6/30/20181,608369N/A446N/A
3/31/20181,567358N/A462N/A
12/31/20171,507337N/A452N/A
9/30/20171,435314N/A462N/A
6/30/20171,356286N/A414N/A
3/31/20171,303274N/A336N/A
12/31/20161,243257N/A306N/A
9/30/20161,144235N/A190N/A
6/30/20161,095229N/A130N/A
3/31/20161,050221N/A173N/A
12/31/20151,000209N/A207N/A
9/30/2015926206N/A271N/A
6/30/2015925235N/A306N/A
3/31/2015914238N/A301N/A
12/31/2014904240N/A286N/A
9/30/2014961240N/A268N/A
6/30/2014942212N/A267N/A
3/31/2014927207N/A281N/A
12/31/2013902201N/A271N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4002Das prognostizierte Gewinnwachstum (16.4% pro Jahr) liegt über der Sparquote (14.7%).

Ertrag vs. Markt: 4002Die Erträge des Unternehmens (16.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (5.9% pro Jahr).

Hohe Wachstumserträge: 4002Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4002Die Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.6% pro Jahr).

Hohe Wachstumseinnahmen: 4002Die Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4002Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.3%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/12/21 01:31
Aktienkurs zum Tagesende2024/12/19 00:00
Gewinne2024/09/30
Jährliche Einnahmen2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Mouwasat Medical Services Company wird von 22 Analysten beobachtet. 13 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jassim Al-JubranAljazira Capital Company
Rim Ben Salah GharbiAlphaMena
Kais KriaaAlphaMena